European IT Hardware Stocks to Watch as Gaming Demand Outpaces Smartphones, Says BofA 
Starboard Value Targets Tripadvisor Board Overhaul Amid Stock Slump 
AstroTurf Expands Footprint at Colorado as Buffaloes Complete Second Installation in 12 Months 
Freedom Finance and Binance Join Forces in Digital Assets 
OpenAI Nears $100 Billion Funding Round at $850 Billion Valuation: Bloomberg Report 
Thomas Pritzker to Step Down as Hyatt Executive Chairman After Epstein Ties Acknowledged 
Waymo Clarifies Role of Remote Workers Amid U.S. Robotaxi Safety Scrutiny 
NAB Shares Hit Record High as First-Quarter Cash Earnings Jump 16% 
Hedge Funds Cut Nvidia, Amazon and Microsoft Stakes as AI Valuation Concerns Rise 
Santos Wins Court Case Over Net Zero and Sustainability Claims 
Qualcomm to Invest $150 Million in India AI Startups, Strengthening Presence in Growing Market 
Goldman Sachs Reportedly Drops Diversity Criteria From Board Candidate Evaluations 
Anderson Cooper to Exit CBS News’ 60 Minutes After Nearly 20 Years 
Luxury Stocks Face Volatility as AI Market Swings and Hedge Fund Bets Rattle LVMH and Kering 
Boeing Secures 50 737 MAX Jet Order from Vietnam Airlines Amid Expanding Global Demand 
Microsoft Plans $50 Billion AI Investment to Accelerate Growth in the Global South 
GAITHERSBURG, Md., May 02, 2018 -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its first quarter 2018 financial and operating results following the close of U.S. financial markets on Wednesday, May 9, 2018.
Conference call details are as follows:
| Date: | May 9, 2018 | |
| Time: | 4:30 p.m. U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events” |
Conference call and webcast replay:
| Dates: | Starting at 7:30 p.m. ET, May 9, 2018 until | |
| 7:30 p.m. ET May 16, 2018 | ||
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 3687883 | |
| Webcast: | www.novavax.com, “Investors”/ “Events”, until August 9, 2017 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Its RSV and influenza nanoparticle vaccine candidates are Novavax’ most advanced clinical programs and are at the forefront of Novavax’ efforts to improve global health. For more information, please visit www.novavax.com.
Contact:
Investors
Erika Trahan
Senior Manager, Investor & Public Relations
[email protected]
240-268-2000
Westwicke Partners
John Woolford
[email protected]
443-213-0506
Media
Sam Brown
Mike Beyer
[email protected]
312-961-2502
